nach oben

Metabolic Brain Disease

Erschienen in:

01.12.2007 | Original Paper

Therapeutic studies in hepatic encephalopathy

verfasst von: Kevin D. Mullen, Piero Amodio, Marsha Y. Morgan

Erschienen in: Metabolic Brain Disease | Ausgabe 3-4/2007

Einloggen, um Zugang zu erhalten

Abstract

This article has arisen from presentations made at the 4th International Hannover Conference on Hepatic Encephalopathy held in Dresden, 2006. Each author as listed describes their presentation given as part of a section entitled “Therapeutic Studies in Hepatic Encephalopathy.” The first section deals with the justification for placebo-controlled trials in hepatic encephalopathy. The other two sections discuss, in detail, outcome parameters for therapeutic studies in the clinical and research setting, respectively.

Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorable disaccharides for hepatic encecephalopathy. A systemic review. Br Med J 328:1040–1050CrossRef

Amodio P, Marchetti P, Del Piccolo F, Campo G, Rizzo C, Iemmolo RM, Gerundi G, Caregaro L, Merkel C, Gatta A (1998) Visual attention in cirrhotic patients: a study on covert visual attention orienting. Hepatology 27:1517–1523PubMedCrossRef

Amodio P, Del Piccolo F, Marchetti P, Angeli P, Iemmolo R, Caregaro L, Merkel C, Gerunda G, Gatta A (1999a) Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 29:1662–1667PubMedCrossRef

Amodio P, Marchetti P, Del Piccolo F, de Tourtchaninoff M, Varghese P, Zuliani C, Campo G, Gatta A, Guerit JM (1999b) Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol 110:1334–1344PubMedCrossRef

Amodio P, Del Piccolo F, Petteno E, Mapelli D, Angeli P, Iemmolo R, Muraca M, Musto C, Gerunda G, Rizzo C, Merkel C, Gatta A (2001) Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 35:37–45PubMedCrossRef

Amodio P, Montagnese S, Gatta A, Morgan MY (2004) Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 19:253–267PubMedCrossRef

Barbaro G, DiLorenzo G, Sodini M, Giancaspro G, Bellomo G, Belloni G, Grisorio B, Annese M, Bacca D, Francavilla R, Barbarini G (1978) Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An Italian, multicenter, double-blind, placebo-controlled cross-over study. Hepatology 28:374–378CrossRef

Bergasa NV (2004) Treatment of the pruritis of cholestasis. Curr Treat Options Gastroenterol 7:501–508PubMedCrossRef

Blanc P, Daures JP, Liautard J, Buttigieg R, Desprez D, Pageaux G, Allaz JL, Parelon G, Larrey D, Michel H (1994) Association lactulose-neomycine versus placebo dans le traitement de l'encephalopathie hepatique aigue. Resultats d’un essai controle randomise. Gastroenterol Clin Biol 18:1063–1068PubMed

Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, Rodés J (1999) Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 30:890–895PubMedCrossRef

Conn HO, Lieberthal MM (1978) The hepatic coma syndromes and lactulose. Williams & Williams, Baltimore

Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72:573–583PubMed

Córdoba J, Alonso J, Rovira A, Jacas C, Sanpedro F, Castells L, Vargas V, Margarit C, Kulisewsky J, Esteban R, Guardia J (2001) The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol 35:598–604PubMedCrossRef

Dawson AM, McLaren J, Sherlock S (1957) Neomycin in the treatment of hepatic coma. Lancet 273: 1263–1268

Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB (2000) Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 45:1549–1552PubMedCrossRef

Douglass A, Al Mardini H, Record C (2001) Amino acid challenge in patients with cirrhosis: a model for the assessment of treatments for hepatic encephalopathy. J Hepatol 34:658–564PubMedCrossRef

Ferenci P, Grimm G, Meryn S, Gamble A (1999) Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 96:240–243

Gentile S, Guarino G, Romano M, Alagia IA, Fierro M, Annunziata S, Magliano PL, Gravina AG, Torella R (2005) A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 3:184–191PubMedCrossRef

Grover VPB, Dresner MA, Forton DM, Counsell S, Larkman DJ, Patel N, Thomas HC, Taylor-Robinson SD (2006) Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy. World J Gastroenterol 12:2969–2978PubMed

Häussinger D (2006) Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 43:1187–90PubMedCrossRef

Häussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M, Gerok W, Hennig J (1994) Proton magnetic resonance spectroscopy on human brain myo-inositol in hypo-osmolality and hepatic encephalopathy. Gastroenterology 107:1475–1480PubMed

Hely MA, Chey T, Wilson A, Williamson PM, O’Sullivan DJ, Rail D, Morris JG (1993) Reliability of the Columbia scale for assessing signs of Parkinson’s disease. Mov Disord 8:466–472

Iversen P, Hansen DA, Bender D, Rodell A, Munk OL, Cumming P, Keiding S (2006) Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy. Eur J Nucl Med Mol Imaging 33:810–816

Iwasa M, Kinosada Y, Nakatsuka A, Watanabe S, Adachi Y (1999) Magnetization transfer contrast of various regions of the brain in liver cirrhosis. AJNR Am J Neuroradiol 20:652–654PubMed

Joebges EM, Heideman M, Schimke N, Hecke H, Ennen JC, Weissenborn K (2003) Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation. J Hepatol 38:273–280PubMedCrossRef

Jover R, Company L, Gutierrez A, Zapater P, Perez-Serra J, Girona E, Aparicio JR, Perez-Mateo M (2003) Minimal hepatic encephalopathy and extrapyramidal signs in patients with cirrhosis. Am J Gastroenterol 98:1599–1604PubMedCrossRef

Kale RA, Gupta RK, Saraswat VA, Hasan KM, Trivedi R, Mishra AM, Rajan P, Pandey CM, Narayana PA (2006) Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 43:698–706PubMedCrossRef

Keiding S, Sørenson M, Bender D, Munk OL, Ott P, Vilstrup H (2006) Brain metabolism of ¹³N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 43:42–50PubMedCrossRef

Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Krüger B, Kuklinski B, Meister H, Otto HJ Rink C, Rösch W, Stauch S (1997) Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 25:1351–1360PubMedCrossRef

Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Häussinger D (2002) Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 35:357–366PubMedCrossRef

Krieger S, Jauss M, Jansen O, Theilmann L, Geissler M, Krieger D (1996) Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis [see comments]. Gastroenterology 111:147–155PubMedCrossRef

Kulisevsky J, Conill J, Avila A, Pujol J, Balanzo J, Capdevila A (1995) Abnormalities of the Bereitschaftspotential and MRI pallidal signal in non-encephalopathic cirrhotic patients. Electroencephalogr Clin Neurophysiol 94:425–431PubMedCrossRef

Lockwood AH, Murphy BW, Donnelly KZ, Mahl TC, Perini S (1993) Positron-emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy. Hepatology 18:1061–1068PubMedCrossRef

Lockwood AH, Weissenborn K, Bokemeyer M, Tietge U, Burchert W (2002) Correlations between cerebral glucose metabolism and neuropsychological test performance in non-alcoholic cirrhotics. Metab Brain Dis 17:29–40PubMedCrossRef

Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodriguez-Martinez D, Fernández-Rodriguez C, Coll I, Pardo A, Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group (2003) Comparison of rifaximin and lactitol in the treatment of acute hepatic encepyhalopathy: Results of a randomized, double-blind, double-dummy controlled clinical trial. J Hepatol 8:51–58CrossRef

Miese F, Kircheis G, Wittsack HJ, Wenserski F, Hemker J, Mödder U, Häussinger D, Cohnen M (2006) ¹H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic encephalopathy. AJNR. Am J Neuroradiol 27:1019–1026PubMed

Montagnese S, Jackson C, Gordon HM, Jethwa N, Sherratt RM, Morgan MY (2005) Smooth pursuit eye movements: does chronic liver disease affect the eye tracking of smooth trajectories. Hepatology 42:772–781PubMedCrossRef

Montagnese S, Jackson C, Morgan MY (2007) Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis. J Hepatol 46:447–458

Mullen KD, Howard R (2005) Is acarbose an effective drug for treating patients with cirrhosis and hepatic encephalopathy? Nat Clin Pract Gastroenterol Hepatol 2:264–265

Natsch S, Kullberg BJ, Hekster YA, van der Meer JW (2003) Selecting outcome parameters in studies aimed at improving rational use of antibiotics—practical considerations. J Clin Pharm Ther 28:475–478PubMedCrossRef

Ortiz M, Córdoba J, Jacas C, Flavià M, Esteban R, Guardia J (2006) Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol 44:104–110PubMedCrossRef

Parsons-Smith BG, Summerskill WHJ, Dawson AM, Sherlock S (1957) The electroencephalograph in liver disease. Lancet II:867–871CrossRef

Patel N, White S, Dhanjal NS, Oatridge A, Taylor-Robinson SD (2004) Changes in brain size in hepatic encephalopathy: a coregistered MRI study. Metab Brain Dis 19:431–445PubMedCrossRef

Pellegrini A, Ubiali E, Orsato R, Schiff S, Gatta A, Castellaro A, Casagrande A, Amodio P (2005) Electroencephalographic staging of hepatic encephalopathy by an artificial neural network and an expert system. Clin Neurophysiol 35:162–167CrossRef

Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, Bezzi M, Attili AF, Merli M (2005) Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 42:674–679PubMedCrossRef

Romero-Gomez M, Córdoba J, Jover R, Del-Olmo JA, Ramírez M, Flavià M, Comapñy N, Rodrigo JM, Felipo V (2006) Usefulness of the measurement of critical flicker frequency in the diagnosis of minimal hepatic encephalopathy [Abstract]. J Hepatol 44(Suppl 2):S93–S230CrossRef

Rovira A, Grive E, Pedraza S, Rovira A, Alonso J (2001) Magnetization transfer ratio values and proton MR spectroscopy of normal-appearing cerebral white matter in patients with liver cirrhosis. AJNR. Am J Neuroradiol 22:1137–1142PubMed

Saxena N, Bhatia M, Joshi YK, Garg PK, Dwivedi SN, Tandon RK (2002) Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver 22:190–197PubMedCrossRef

Schiff S, Vallesi A, Mapelli D, Orsato R, Pellegrini A, Umiltà C, Gatta A, Amodio P (2005) Impairment of response inhibition precedes motor alteration in the early stage of liver cirrhosis: a behavioral and electrophysiological study. Metab Brain Dis 20:381–392PubMedCrossRef

Schomerus H, Hamster W (1998) Neuropsychological aspects of portal-systemic encephalopathy. Metab Brain Dis 13:361–377PubMedCrossRef

Sharma P, Sharma BC, Sarin SK, Puri V (2006) Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy [Abstract]. J Hepatol 44(Suppl 2):S93–S94, 232CrossRef

Sigal SH, Stanca CM, Kontorinis N, Bodian C, Ryan E (2006) Diabetes Mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol 101:1490–1496

Strauss E, da Costa MF (1998) The importance of bacterial infections as precipitating factors of chronic hepatic encephalopathy in cirrhosis. Hepatogastroenterology 45:900–904PubMed

Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, de Sá MF (1992) Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatology 39:542–545

Timmermann L, Gross J, Butz M, Kircheis G, Häussinger D, Schnitzler A (2003) Mini-asterixis in hepatic encephalopathy induced by pathologic thalmo-motor-cortical coupling. Neurology 61:689–692PubMed

Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N (2001) Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci 13:229–242PubMed

Wein C, Koch H, Popp B, Oehler G, Schauder P (2004) Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 39:739–745PubMedCrossRef

Weissenborn K, Scholz M, Hinrichs H, Wiltfang J, Schmidt FW, Künkel H (1990) Neuropsychological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol 75:289–295PubMedCrossRef

Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H (2001a) Neuropsychological characterization of hepatic encephalopathy. J Hepatol 34:768–773PubMedCrossRef

Weissenborn K, Heidenreich S, Ennen J, Rückert N, Hecker H (2001b) Attention deficits in minimal hepatic encephalopathy. Metab Brain Dis 16:13–19PubMedCrossRef

Weissenborn K, Heidenreich S, Giewekemeyer K, Rückert N, Hecker H (2003) Memory function in early hepatic encephalopathy. J Hepatol 39:320–325PubMedCrossRef

Weissenborn K, Giewekemeyer K, Heidenreich S, Bokemeyer M, Berding G, Ahl B (2005) Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 20:359–367PubMedCrossRef

Zafiris O, Kircheis G, Rood HA, Boers F, Häussinger D, Zilles K (2004) Neural mechanism underlying impaired visual judgment in the dysmetabolic brain: fMRI study. NeuroImage 22:541–552PubMedCrossRef

Titel: Therapeutic studies in hepatic encephalopathy
verfasst von: Kevin D. Mullen
Piero Amodio
Marsha Y. Morgan
Publikationsdatum: 01.12.2007
Verlag: Springer US
Erschienen in: Metabolic Brain Disease / Ausgabe 3-4/2007
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-007-9061-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3-4/2007

Aquaporin-4 in hepatic encephalopathy

Controversies in ammonia metabolism: implications for hepatic encephalopathy

Caecal ligation and puncture in the rat mimics the pathophysiological changes in human sepsis and causes multi-organ dysfunction

New concepts in the mechanism of ammonia-induced astrocyte swelling

The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy